back to US directory
us clinical guidance

Pediatric ADHD diagnosis and longitudinal treatment

AAP-aligned multi-setting evaluation, comorbidity assessment, age-specific behavioral and medication treatment, school support and monitoring.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals caring for children and adolescents
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Children from age four years to their eighteenth birthday, matching the 2019 AAP guideline. Adult ADHD is not covered by that source and should not be inferred from this page. Developmental variation, learning disorders, sleep problems, trauma, anxiety, depression, substance use and other conditions can mimic or coexist with ADHD and require deliberate assessment.
sources for this section:AAP ADHD 2019

The Bottom Line

  • Initiate evaluation for children aged four through seventeen with academic or behavioral concerns and symptoms of inattention, hyperactivity or impulsivity, using information from more than one setting.
  • Apply current diagnostic criteria, document impairment and obtain reports from parents, teachers, school personnel and the young person when developmentally appropriate; a rating scale alone does not make the diagnosis.
  • Screen for emotional, behavioral, developmental and physical coexisting conditions, including anxiety, depression, learning or language disorder, autism, tics, sleep apnea and substance use.
  • Use age-specific treatment: parent training in behavior management first for preschool children, and FDA-approved medication with behavioral and educational supports for school-age children and adolescents as indicated.
sources for this section:AAP ADHD 2019

Practical clinical workflow

1
Take developmental, medical, family, school, sleep, trauma and substance histories, check hearing and vision, review records and define concrete impairment and goals with the family and child.
2
Collect validated rating scales from multiple observers, reconcile discrepancies and assess duration, onset and alternative causes before confirming the diagnosis.
3
Create a chronic-care plan with behavioral support, school partnership and an individualized medication trial when appropriate, titrating to maximal benefit with tolerable adverse effects.
4
Monitor symptoms and function in each setting, blood pressure, heart rate, growth, sleep, appetite, mood, misuse and diversion; revisit the diagnosis and plan during transitions.
sources for this section:AAP ADHD 2019

Safety boundaries and escalation

  • Assess suicidal thinking, severe mood symptoms, psychosis, substance use, abuse or unsafe behavior directly and obtain urgent mental-health support when risk is acute.
  • Before medication, review cardiac symptoms and family history, interactions, seizures, tics and prior adverse effects; investigate a concerning cardiac history rather than ordering indiscriminate tests for every child.
  • Adolescents need confidential discussion, consent and assent, driving safety, diversion prevention and a planned transition to adult care before pediatric services end.
  • Do not use school performance alone to diagnose or judge treatment; learning disability, inequitable instruction, language difference and psychosocial adversity may require different interventions.
sources for this section:AAP ADHD 2019

Localization

The AAP guideline is specific to the US pediatric medical home and interacts with IDEA, Section 504 and state school systems; diagnosis does not automatically determine educational eligibility. FDA labeling, controlled-substance rules and telehealth prescribing vary.
sources for this section:AAP ADHD 2019

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American Academy of Pediatrics Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactive DisorderClinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and AdolescentsDOI 10.1542/peds.2019-2528 路 published 2019-09-30 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.